Published in Dialogues Clin Neurosci on January 01, 2011
Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull (2012) 2.30
Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol (2012) 1.25
The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol (2014) 1.15
Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice. Psychiatr Clin North Am (2012) 1.04
Quantifying clinical relevance in the treatment of schizophrenia. Clin Ther (2011) 0.87
Amphetamine effects on MATRICS Consensus Cognitive Battery performance in healthy adults. Psychopharmacology (Berl) (2013) 0.77
A Meta-analytic Review of Non-specific Effects in Randomized Controlled Trials of Cognitive Remediation for Schizophrenia. Psychiatr Q (2016) 0.76
Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalation. BMC Psychiatry (2015) 0.76
Transdiagnostic Clinical Global Impression Scoring for Routine Clinical Settings. Behav Sci (Basel) (2017) 0.75
The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull (1987) 51.07
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med (2005) 28.99
Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry (1988) 12.39
Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA (2005) 10.16
Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry (2006) 9.44
Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis (2006) 8.23
Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med (2009) 7.89
Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA (2009) 6.91
Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry (2005) 6.27
Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs (2005) 5.84
A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med (2002) 5.65
Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry (2011) 5.46
Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA (2003) 5.19
Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand (2007) 4.51
Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res (2011) 4.22
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry (2006) 4.12
Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry (2003) 3.85
Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry (1999) 3.48
Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med (2011) 3.36
Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry (2006) 3.35
Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry (2003) 3.18
Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry (2000) 2.93
Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. J Clin Psychiatry (2008) 2.86
Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry (2005) 2.62
Social cognition in schizophrenia: an NIMH workshop on definitions, assessment, and research opportunities. Schizophr Bull (2008) 2.59
Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry (1992) 2.59
Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Arch Gen Psychiatry (2005) 2.58
A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry (2008) 2.53
First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry (2008) 2.24
Optimizing early prediction for antipsychotic response in schizophrenia. J Clin Psychopharmacol (2006) 2.17
Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev (2010) 2.13
Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry (2003) 2.11
The value, qualification, and regulatory use of surrogate end points in drug development. Clin Pharmacol Ther (2009) 2.08
Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry (1999) 2.06
Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Arch Gen Psychiatry (1983) 1.92
Strengthening clinical effectiveness trials: equipoise-stratified randomization. Biol Psychiatry (2001) 1.88
Evidence for onset of antipsychotic effects within the first 24 hours of treatment. Am J Psychiatry (2005) 1.83
The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom (2003) 1.83
From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry (2010) 1.81
Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. J Clin Psychiatry (2006) 1.69
Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. Neuropsychopharmacology (2010) 1.67
Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry (2010) 1.65
Improving employment outcomes for persons with severe mental illnesses. Arch Gen Psychiatry (2002) 1.57
A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. Am J Psychiatry (2002) 1.55
Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry (2005) 1.49
Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology (2010) 1.47
Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res (2008) 1.45
Cognitive and clinical predictors of success in vocational rehabilitation in schizophrenia. Schizophr Res (2004) 1.40
What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it? Schizophr Bull (2008) 1.38
Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. Schizophr Bull (2007) 1.36
Sources of unreliability in depression ratings. J Clin Psychopharmacol (2009) 1.35
Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev (2009) 1.32
Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology (2010) 1.31
Site versus centralized raters in a clinical depression trial: impact on patient selection and placebo response. J Clin Psychopharmacol (2010) 1.29
Bias reduction with an adjustment for participants' intent to dropout of a randomized controlled clinical trial. Clin Trials (2007) 1.26
Early prediction of antipsychotic nonresponse among patients with schizophrenia. J Clin Psychiatry (2007) 1.24
Selection bias in clinical trials with antipsychotics. J Clin Psychopharmacol (2000) 1.23
A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry (2009) 1.20
Control group bias in randomized atypical antipsychotic medication trials for schizophrenia. Arch Gen Psychiatry (2005) 1.20
Developments in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychotics. J Clin Psychiatry (2011) 1.18
Interview quality and signal detection in clinical trials. Am J Psychiatry (2005) 1.17
Pharmacological treatments for first-episode schizophrenia. Schizophr Bull (2005) 1.14
Report from the working group conference on multisite trial design for cognitive remediation in schizophrenia. Schizophr Bull (2010) 1.13
Dropout rates in randomised antipsychotic drug trials. Psychopharmacology (Berl) (2001) 1.13
Prevention of negative symptom psychopathologies in first-episode schizophrenia: two-year effects of reducing the duration of untreated psychosis. Arch Gen Psychiatry (2008) 1.13
The ethical basis of psychiatric research: conceptual issues and empirical findings. Compr Psychiatry (1998) 1.13
An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry (2011) 1.09
The dimensions of clinical and cognitive change in schizophrenia: evidence for independence of improvements. Psychopharmacology (Berl) (2006) 1.07
Safety reporting in randomized trials of mental health interventions. Am J Psychiatry (2004) 1.07
Methodological issues in current antipsychotic drug trials. Schizophr Bull (2008) 1.07
Subject selection biases in clinical trials: data from a multicenter schizophrenia treatment study. J Clin Psychopharmacol (1996) 1.07
Time course for antipsychotic treatment response in first-episode schizophrenia. Am J Psychiatry (2006) 1.05
Attitudes of patients with schizophrenia toward placebo-controlled clinical trials. J Clin Psychiatry (2003) 1.04
Letter: Clozapine and agranulocytosis. Lancet (1975) 1.02
Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia. Arch Gen Psychiatry (1982) 0.99
Implications of clinical trial design on sample size requirements. Schizophr Bull (2008) 0.99
Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories. Biol Psychiatry (2010) 0.98
Antipsychotic drugs for first-episode schizophrenia: a comparative review. CNS Drugs (2009) 0.98
Where to position clozapine: re-examining the evidence. Can J Psychiatry (2010) 0.97
Trajectories and antecedents of treatment response over time in early-episode psychosis. Schizophr Bull (2008) 0.94
Subjective well-being under the neuroleptic treatment and its relevance for compliance. Acta Psychiatr Scand Suppl (2005) 0.94
Time to treatment response in first-episode schizophrenia: should acute treatment trials last several months? J Clin Psychiatry (2011) 0.92
Unanswered questions in schizophrenia clinical trials. Schizophr Bull (2008) 0.90
The different trajectories of antipsychotic response: antipsychotics versus placebo. Psychol Med (2010) 0.90
Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis. Psychiatry Res (2010) 0.89
Antipsychotic-associated all-cause and cardiac mortality: what should we worry about and how should the risk be assessed? Acta Psychiatr Scand (2010) 0.88
Treatment response trajectories and their antecedents in recent-onset psychosis: a 2-year prospective study. J Clin Psychopharmacol (2010) 0.87
Suicidality in schizophrenia: a review of the evidence for risk factors and treatment options. Curr Psychiatry Rep (2002) 0.85
Trial design issues and treatment effect modeling in multi-regional schizophrenia trials. Pharm Stat (2010) 0.84
Predicting outcome of neuroleptic treatment on the basis of subjective response and early clinical improvement. J Clin Psychiatry (1987) 0.84
Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disorders. Schizophr Res (2008) 0.83
Neuroleptic dysphoria: revisiting the concept 50 years later. Acta Psychiatr Scand Suppl (2005) 0.82
Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia. BMC Psychiatry (2011) 0.82
Feasibility of placebo-controlled clinical trials of antipsychotic compounds in Europe. Psychopharmacology (Berl) (2002) 0.82
The prediction of acute response, remission and general outcome of neuroleptic treatment in acute schizophrenic patients. Pharmacopsychiatria (1983) 0.81
Implementation of the thinking skills for work program in a psychosocial clubhouse. Psychiatr Rehabil J (2010) 0.80
A roadmap to disentangle the molecular etiology of schizophrenia. Eur Psychiatry (2008) 0.79
Innovations in clinical research design and conduct in psychiatry: shifting to pragmatic approaches. Psychiatry Investig (2009) 0.79
Individualizing antipsychotic treatment selection in schizophrenia: characteristics of empirically derived patient subgroups. Eur Psychiatry (2011) 0.77
Low dose fluphenazine decanoate in maintenance treatment of schizophrenia. Psychiatry Res (1979) 0.76
Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA (2009) 6.91
Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry (2005) 6.27
Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res (2011) 4.22
Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry (2004) 3.59
Physical health monitoring of patients with schizophrenia. Am J Psychiatry (2004) 3.54
Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry (2007) 3.26
Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry (2003) 3.18
Why do clinical trials fail? The problem of measurement error in clinical trials: time to test new paradigms? J Clin Psychopharmacol (2007) 2.99
Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol (2009) 2.88
What does the PANSS mean? Schizophr Res (2005) 2.86
Prescription practices in the treatment of first-episode schizophrenia spectrum disorders: data from the national RAISE-ETP study. Am J Psychiatry (2014) 2.81
Runs of homozygosity reveal highly penetrant recessive loci in schizophrenia. Proc Natl Acad Sci U S A (2007) 2.81
Disrupted in schizophrenia 1 (DISC1): association with schizophrenia, schizoaffective disorder, and bipolar disorder. Am J Hum Genet (2004) 2.71
Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol (2006) 2.60
Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). Am J Psychiatry (2010) 2.57
Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided? J Clin Psychiatry (2013) 2.50
Clinical implications of Brief Psychiatric Rating Scale scores. Br J Psychiatry (2005) 2.38
Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull (2012) 2.30
The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry (2003) 2.15
Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull (2008) 1.93
Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132. Ann Surg Oncol (2011) 1.86
Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2012) 1.82
Attention-deficit/hyperactivity disorder: a preliminary diffusion tensor imaging study. Biol Psychiatry (2005) 1.80
Tardive dyskinesia circa 2006. Am J Psychiatry (2006) 1.78
Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry (2013) 1.76
Wide excision or Mohs micrographic surgery for the treatment of primary dermatofibrosarcoma protuberans. Am J Clin Oncol (2010) 1.72
The serotonin 1A receptor gene confer susceptibility to mood disorders: results from an extended meta-analysis of patients with major depression and bipolar disorder. Eur Arch Psychiatry Clin Neurosci (2012) 1.70
Clinical and neuropsychological correlates of white matter abnormalities in recent onset schizophrenia. Neuropsychopharmacology (2007) 1.70
Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J Clin Psychiatry (2007) 1.67
Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology (2006) 1.66
Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res (2006) 1.65
Obesity and coronary risk in patients treated with second-generation antipsychotics. Eur Arch Psychiatry Clin Neurosci (2010) 1.61
Genetic variation in DTNBP1 influences general cognitive ability. Hum Mol Genet (2006) 1.61
Association of genetic variation in the MET proto-oncogene with schizophrenia and general cognitive ability. Am J Psychiatry (2010) 1.58
Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. Am J Psychiatry (2006) 1.57
White matter abnormalities in first-episode schizophrenia or schizoaffective disorder: a diffusion tensor imaging study. Am J Psychiatry (2005) 1.56
Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res (2012) 1.56
Patterns of stress in schizophrenia. Psychiatry Res (2008) 1.55
Sudden deaths in psychiatric patients. J Clin Psychiatry (2011) 1.53
Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study. Am J Psychiatry (2014) 1.50
Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry (2003) 1.49
Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry (2005) 1.49
Clozapine as a first treatment for schizophrenia. Am J Psychiatry (2003) 1.49
Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology (2010) 1.47
Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry (2003) 1.47
Molecular differentiation of schizoaffective disorder from schizophrenia using BDNF haplotypes. Br J Psychiatry (2009) 1.47
Use of remote centralized raters via live 2-way video in a multicenter clinical trial for schizophrenia. J Clin Psychopharmacol (2008) 1.46
Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol Psychiatry (2007) 1.45
Association of the DTNBP1 locus with schizophrenia in a U.S. population. Am J Hum Genet (2004) 1.45
Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res (2008) 1.45
Cognitive development in schizophrenia: follow-back from the first episode. J Clin Exp Neuropsychol (2006) 1.42
DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. Am J Psychiatry (2006) 1.41
A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg (2009) 1.39
Soft tissue sarcoma. J Natl Compr Canc Netw (2010) 1.34
Electrophysiological indices of automatic and controlled auditory information processing in first-episode, recent-onset and chronic schizophrenia. Biol Psychiatry (2006) 1.34
Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacology (2007) 1.34
Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review. Prim Care Companion J Clin Psychiatry (2009) 1.33
Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection. Schizophr Res (2005) 1.27
Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology (2007) 1.27
Differentiation in the preonset phases of schizophrenia and mood disorders: evidence in support of a bipolar mania prodrome. Schizophr Bull (2007) 1.26
Reduced frontal white matter integrity in early-onset schizophrenia: a preliminary study. Biol Psychiatry (2004) 1.26
Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol (2012) 1.25
In silico and in vivo approach to elucidate the inflammatory complexity of CD14-deficient mice. Mol Med (2006) 1.25
Genome-wide association study implicates NDST3 in schizophrenia and bipolar disorder. Nat Commun (2013) 1.25
Strategies for mHealth research: lessons from 3 mobile intervention studies. Adm Policy Ment Health (2015) 1.25
Early prediction of antipsychotic nonresponse among patients with schizophrenia. J Clin Psychiatry (2007) 1.24
Sex differences in frontal lobe white matter microstructure: a DTI study. Neuroreport (2003) 1.23
White matter abnormalities in early-onset schizophrenia: a voxel-based diffusion tensor imaging study. J Am Acad Child Adolesc Psychiatry (2005) 1.23
Disrupted in schizophrenia 1 genotype and positive symptoms in schizophrenia. Biol Psychiatry (2006) 1.22
DISC1 is associated with prefrontal cortical gray matter and positive symptoms in schizophrenia. Biol Psychol (2007) 1.21
Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Arch Gen Psychiatry (2012) 1.20
DISC1 and neurocognitive function in schizophrenia. Neuroreport (2005) 1.19
Dysbindin genotype and negative symptoms in schizophrenia. Am J Psychiatry (2006) 1.17
Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry (2005) 1.16
Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis. J Clin Psychiatry (2010) 1.16
Soft tissue sarcoma, version 2.2014. J Natl Compr Canc Netw (2014) 1.15
When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. Schizophr Res (2011) 1.15
Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J Clin Psychiatry (2006) 1.14
COMT genetic variation confers risk for psychotic and affective disorders: a case control study. Behav Brain Funct (2005) 1.14
Smaller anterior hippocampal formation volume in antipsychotic-naive patients with first-episode schizophrenia. Am J Psychiatry (2003) 1.14
Pharmacological treatments for first-episode schizophrenia. Schizophr Bull (2005) 1.14
Safety and tolerability of antipsychotic polypharmacy. Expert Opin Drug Saf (2012) 1.13
Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry (2013) 1.12
Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications. Am J Psychiatry (2005) 1.11
The genetics of symptom-based phenotypes: toward a molecular classification of schizophrenia. Schizophr Bull (2008) 1.11
Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study. Schizophr Res (2013) 1.11
Cost of antipsychotic polypharmacy in the treatment of schizophrenia. BMC Psychiatry (2008) 1.09
Impairments in perceptual competency and maintenance on a visual delayed match-to-sample test in first-episode schizophrenia. Arch Gen Psychiatry (2003) 1.09
Implications for health and disease in the genetic signature of the Ashkenazi Jewish population. Genome Biol (2012) 1.08
Methodological issues in current antipsychotic drug trials. Schizophr Bull (2008) 1.07
Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. J Clin Epidemiol (2013) 1.05
Implication of a rare deletion at distal 16p11.2 in schizophrenia. JAMA Psychiatry (2013) 1.05
CD204 suppresses large heat shock protein-facilitated priming of tumor antigen gp100-specific T cells and chaperone vaccine activity against mouse melanoma. J Immunol (2011) 1.04
Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis. Ann Surg Oncol (2009) 1.03
Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disord (2008) 1.03
Magnetic resonance imaging predictors of treatment response in first-episode schizophrenia. Schizophr Bull (2010) 1.02
The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. Cancer (2009) 1.02
A contemporary analysis of morbidity and outcomes in cytoreduction/hyperthermic intraperitoneal chemoperfusion. Cancer Med (2013) 1.02
Predicting antipsychotic drug response - replication and extension to six weeks in an international olanzapine study. Schizophr Res (2008) 0.98
Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality. J Child Adolesc Psychopharmacol (2009) 0.98